"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...
The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door ...
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. "Too ...
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the ...